Though still limited, a Subjective Cognitive Impairment Cohort (SCIENCe) study has found that the SCD-plus criteria age ≥ 60 and APOE ε4 carriership were associated with an increased risk of preclinical AD, which is defined by amyloid positivity on either PET or cerebrospinal fluid (CSF) (Slot et al. 2018). The gene discussed is APOE; the disease is Alzheimer disease.